Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Nasally delivered SARS-CoV-2 vaccines: future promise and challenges.

Shaw RH., (2023), Lancet Respir Med, 11, 1038 - 1039

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect, 86, 574 - 583

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157

Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing

Delpuech O. et al, (2022), Scientific Reports, 12

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060

Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Hodgson SH. et al, (2022), Clin Transl Sci, 15, 524 - 534

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Stuart ASV. et al, (2022), Lancet, 399, 36 - 49

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Dejnirattisai W. et al, (2021), Lancet

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.

Munro APS. et al, (2021), Lancet

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Clemens SAC. et al, (2021), Nature Communications, 12

Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study.

Mo Y. et al, (2021), PLoS Med, 18

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Flaxman A. et al, (2021), Lancet, 398, 981 - 990

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Liu X. et al, (2021), Lancet, 398, 856 - 869

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.

Lumley SF. et al, (2021), Clin Infect Dis, 73, e699 - e709

Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Liu X. et al, (2021), SSRN Electronic Journal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.

Shaw RH. et al, (2021), Lancet, 397, 2043 - 2046

Transmission dynamics of SARS-CoV-2 in the hospital setting

Mo Y. et al, (2021)

SARS-CoV-2 within-host diversity and transmission

Lythgoe KA. et al, (2021), Science (New York, N.Y.), 372

SARS-CoV-2 within-host diversity and transmission.

Lythgoe KA. et al, (2021), Science, 372

Load More